论文部分内容阅读
目的探讨ｐ１６、ｃｙｃｌｉｎＤ１蛋白表达与膀胱移行细胞癌（ＴＣＣ）临床分期、病理分级及预后的关系。方法采用免疫组化Ｓ－Ｐ法检测 ５９例膀胱ＴＣＣ中ｐ１６、ｃｙｃｌｉｎＤ１蛋白的表达。结果膀胱ＴＣＣ 组织中 ｐ１６蛋白阳性表达率为 ４２．４％，随临床分期、病理分级增高而下降，ｃｙｃｌｉｎＤ１蛋白阳性表达率为 ６１％，随临床分期增高而上升；ｐ１６、ｃｙｃｌｉｎＤ１蛋白表达间呈负相关；ｐ１６阳性组和 ｃｙｃｌｉｎＤ１阴性组复发率明显低于 ｐ１６阴性组和ｃｙｃｌｉｎＤ１阳性组；ｐ１６阳性组和 ｃｐｃｌｉｎＤ１阴性组 ３年存活率明显高于 ｐ１６阴性组和 ｃｙｃｌｉｎＤ１阳性组。结论ｐ１６、ｃｙｃｌｉｎＤ１蛋白检测可作为膀胱ＴＣＣ辅助诊断及预后判断的参考指标。
Objective To investigate the relationship between the expression of p16, cyclinD1 and the clinical stage, pathological grade and prognosis of bladder transitional cell carcinoma (TCC). Methods Immunohistochemical S-P method was used to detect the expression of p16 and cyclinD1 in 59 cases of bladder TCC. Results The positive rate of p16 protein in bladder TCC tissues was 42.4%, which was decreased with the increase of clinical stage and pathological grade. The positive rate of cyclinD1 protein was 61%, which increased with the increase of clinical stage. The expression of p16 and cyclinD1 protein was negative . The relapse rate of p16 positive group and cyclinD1 negative group was significantly lower than that of p16 negative group and cyclinD1 positive group. The 3-year survival rates of p16 positive group and cpclin D1 negative group were significantly higher than that of p16 negative group and cyclin D1 positive group. Conclusion The detection of p16 and cyclinD1 protein can be used as a reference index for diagnosis and prognosis of bladder TCC.